

Drugmaker to sell cheaper generic rival to EpiPen injectors

December 6 2018, by Linda A. Johnson



This image provided by Sandoz Inc. shows a new epinephrine injector by Sandoz, Inc. Amid persistent shortages of EpiPens and other emergency autoinjectors that treat life-threatening allergic reactions, generic drugmaker



Sandoz says that early next year it will launch a slightly cheaper rival in the U.S. Sandoz said Thursday, Dec. 6, 2018, that it plans to sell a pair of its generic autoinjectors for \$250 without insurance. (Sandoz Inc. via AP)

A generic drugmaker plans to start selling a slightly cheaper version of the EpiPen in the U.S. early next year.

The penlike injectors are used to treat life-threatening <u>allergic reactions</u>. Brand-name EpiPen, which dominates the market, has been in short supply since spring because of production problems.

Drugmaker Sandoz said Thursday the price of two generic injectors will be \$250 without insurance. Two other generics on the <u>market</u> in the U.S. cost \$300 a pair. Brand-name EpiPens sold by Mylan cost at least twice as much.

The price people pay varies, though, depending on insurance and discounts.

Mylan was blasted in the past for price hikes that pushed the price over \$600. It responded by selling its own generic.

© 2018 The Associated Press. All rights reserved.

Citation: Drugmaker to sell cheaper generic rival to EpiPen injectors (2018, December 6) retrieved 3 May 2024 from <u>https://medicalxpress.com/news/2018-12-drugmaker-cheaper-rival-epipen-injectors.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.